Breast Cancer Stages: What Each Stage Means for Treatment and Outlook

Written by North Editorial Staff | Clinically reviewed by Laura Morrissey, RN, BSN | Last reviewed: March 2026

Key Takeaways

  • Breast cancer is staged 0 through IV using the TNM system — Tumor size, lymph Node involvement, and Metastasis — plus biological markers like ER, PR, and HER2 status that can shift your stage up or down.

  • Stage 0 (DCIS) and Stage I carry 5-year survival rates approaching 99–100%; Stage IV (metastatic) has a 5-year survival rate of approximately 28–32%, though that number is improving steadily with newer treatments.

  • Your tumor’s biology — hormone receptor status, HER2 expression, grade, and genomic test results — matters as much as tumor size for deciding the right treatment.

  • Targeted therapies such as CDK4/6 inhibitors (for hormone receptor-positive disease) and anti-HER2 agents like trastuzumab and T-DXd have meaningfully extended survival even at advanced stages.

  • Clinical trials are actively enrolling patients at every stage — including early-stage and metastatic — and offer access to treatments that may not yet be available through standard care.

How Breast Cancer Is Staged: An Overview

Breast cancer is staged 0 through IV using the TNM system (Tumor size, Node involvement, Metastasis) plus biological markers — ER, PR, HER2, grade, and Ki-67. The stage at diagnosis is one of the most important factors determining treatment options and prognosis. Together, these factors help your care team understand how far the cancer has grown, how aggressively it is likely to behave, and which treatments are most likely to work for you.

Understanding your stage is not just a number. It is a shorthand for a detailed picture of your cancer, which shapes many of the decisions ahead.

The TNM Staging System Explained

The TNM system has been the international standard for cancer staging for decades, but breast cancer staging changed significantly when the American Joint Committee on Cancer (AJCC) released its 8th edition staging manual, adopted on January 1, 2018. Here is what each letter means.

T — Tumor size and extent

  • T0: No evidence of a primary tumor

  • T1: Tumor 2 cm or smaller (T1a ≤0.5 cm, T1b 0.5–1 cm, T1c 1–2 cm)

  • T2: Tumor larger than 2 cm but 5 cm or smaller

  • T3: Tumor larger than 5 cm

  • T4: Tumor of any size that has grown into the chest wall or skin

N — Lymph node involvement

  • N0: No lymph node involvement

  • N1: Cancer found in 1–3 axillary (underarm) lymph nodes, or internal mammary nodes (microscopic)

  • N2: Cancer in 4–9 axillary lymph nodes, or clinically detected internal mammary nodes

  • N3: Cancer in 10 or more axillary lymph nodes, or spread to supraclavicular or infraclavicular nodes

M — Metastasis

  • M0: No distant spread detected

  • M1: Cancer has spread to distant organs (bone, liver, lung, brain, or elsewhere)

How Biology Modifies Your Stage

The most significant change the AJCC 8th edition introduced is that the final “prognostic stage” — the stage that guides treatment decisions — is determined not by TNM anatomy alone, but by combining TNM with tumor biomarker status: estrogen receptor (ER), progesterone receptor (PR), HER2, histologic grade, and in certain cases, results from multigene assays like Oncotype DX.

What this means in practice: a large ER-positive, HER2-negative, Grade 1 tumor that would have been Stage IIB under the old system might be reclassified as Stage IA because its biology indicates a favorable prognosis. Conversely, a small HER2-positive tumor with lymph node involvement might be upstaged because HER2 amplification signals more aggressive behavior.

According to a validation study of 54,727 patients in the California Cancer Registry, the AJCC 8th edition prognostic staging system provided more accurate prognostic information than anatomic staging alone. This means your stage is now a more precise and meaningful reflection of your individual cancer’s behavior.

Stage 0: DCIS — Cancer in Place

What Is Stage 0 (DCIS)?

Ductal carcinoma in situ (DCIS) is the earliest form of breast cancer. It is so early that many experts debate whether it should be called cancer at all. “In situ” is Latin for “in place”: the abnormal cells are confined entirely within the milk ducts and have not broken through the duct walls into surrounding breast tissue. Because the cells have not invaded nearby tissue, they cannot spread to lymph nodes or other organs.

DCIS is sometimes called Stage 0 or pre-invasive cancer. It accounts for roughly 20% of new breast cancer diagnoses in the United States, according to the American Cancer Society. Most cases are found through mammography, often before any lump or symptom develops. Left untreated, some cases of DCIS will progress to invasive breast cancer over time, which is why treatment is generally recommended, but not all cases would progress if left alone.

Treatment for Stage 0

The goal of DCIS treatment is to prevent progression to invasive cancer. Standard options include:

  • Breast-conserving surgery (lumpectomy) followed by radiation therapy, which is the most common approach. The RTOG 9804 trial found local recurrence rates at 15 years were 7.1% after radiotherapy compared to 15.1% with observation alone.  

  • Mastectomy, the removal of the entire breast, for larger areas of DCIS, high-grade DCIS, or patient preference. Radiation is not typically needed after mastectomy.

  • Hormone therapy — tamoxifen for premenopausal patients, and tamoxifen or an aromatase inhibitor for postmenopausal patients — is recommended for five years when the DCIS is ER-positive. In the NSABP B-24 trial, women who took tamoxifen had fewer breast cancer events than those who did not (8.2% versus 13.4%).

Prognosis for DCIS is excellent. The 10-year survival rate is approximately 98%, and breast cancer mortality at 20 years of follow-up is around 3%. Most people treated for DCIS go on to live their full life expectancy.

Stage I: Early, Localized Breast Cancer

Stage IA

At Stage IA, the tumor is 2 cm or smaller and has not spread to any lymph nodes. Under the AJCC 8th edition, tumors with very favorable biology — Grade 1, ER-positive, HER2-negative — may be classified as Stage IA even if they are slightly larger than 2 cm due to their low-risk profile.

Stage IA is also diagnosed when no tumor is found in the breast but a microscopic cluster of cancer cells (a micrometastasis of 0.2 mm or smaller) is found in a sentinel lymph node.

Stage IB

Stage IB applies to small tumors (or no detectable tumor) with micrometastases — cancer cells measuring between 0.2 mm and 2 mm — in one to three lymph nodes. The distinction between IA and IB reflects the presence of very limited lymph node involvement, but prognosis remains extremely favorable.

Treatment and Outlook for Stage I

The general approach to Stage I breast cancer is surgery first: either a lumpectomy (breast-conserving surgery) followed by radiation therapy, or mastectomy. For lumpectomy patients, radiation significantly reduces the risk of local recurrence.

Additional treatments depend heavily on your tumor’s biology:

  • Hormone therapy (tamoxifen for five to ten years, or an aromatase inhibitor for postmenopausal patients) for ER-positive tumors

  • Targeted therapy (trastuzumab and pertuzumab) for HER2-positive tumors

  • Chemotherapy — may be recommended depending on grade, Ki-67 level, and genomic test results. For many patients with Stage I, ER-positive, HER2-negative disease, an Oncotype DX test can determine whether chemotherapy adds meaningful benefit beyond hormone therapy alone.

According to the American Cancer Society, using SEER data from patients diagnosed 2014–2020, the 5-year relative survival rate for localized breast cancer (encompassing most Stage I disease) is approximately 99%. This is one of the most encouraging statistics in oncology. Stage I breast cancer is highly treatable, and the majority of patients achieve long-term remission.

Stage II: Locally Advanced Breast Cancer

Stage IIA

Stage IIA covers several scenarios:

  • A tumor 2 cm or smaller that has spread to 1–3 axillary lymph nodes

  • A tumor larger than 2 cm but 5 cm or smaller with no lymph node involvement

  • No tumor found in the breast, but cancer is present in 1–3 axillary lymph nodes

Biological factors can shift Stage IIA tumors up or down. A highly favorable ER-positive, Grade 1 tumor may be reclassified as Stage IA; an aggressive HER2-positive tumor may be reclassified as Stage IIA even if it would have been Stage I under the old anatomic system.

Stage IIB

Stage IIB includes:

  • A tumor larger than 2 cm but 5 cm or smaller with cancer in 1–3 lymph nodes

  • A tumor larger than 5 cm with no lymph node involvement

A tumor larger than 5 cm with no lymph node spread reflects local bulk but no evidence of systemic dissemination, which is why it sits at Stage IIB rather than Stage III.

Treatment and Outlook for Stage II

Treatment for Stage II breast cancer typically involves a combination of local and systemic therapies:

  • Surgery — lumpectomy plus radiation, or mastectomy; axillary lymph node evaluation via sentinel node biopsy or axillary dissection

  • Chemotherapy — frequently recommended, especially for triple-negative breast cancer (ER-negative, PR-negative, HER2-negative), HER2-positive tumors, and high-grade or high-Oncotype DX score tumors

  • Targeted therapy — trastuzumab (and pertuzumab) for HER2-positive disease, typically for one year

  • Hormone therapy — for ER-positive tumors, often continuing for five to ten years after surgery

  • Radiation — routinely recommended after lumpectomy; may also be recommended after mastectomy for large tumors or multiple positive lymph nodes

According to ACS data, the 5-year relative survival rate for Stage II breast cancer is approximately 86% for regional-stage disease (which encompasses Stage II and III combined in SEER’s regional category). Stage IIA patients tend to do better than Stage IIB, but outcomes for both are meaningfully improved by modern multimodal treatment.

Learn more about breast cancer treatment options and how treatment is chosen based on stage and biology.

Stage III: Locally Advanced Breast Cancer

Stage IIIA

Stage IIIA applies when:

  • The tumor is any size and has spread to 4–9 axillary lymph nodes, or

  • The tumor is larger than 5 cm and cancer is found in 1–3 axillary lymph nodes with certain nodal characteristics

At Stage IIIA, the cancer remains confined to the breast region and has not spread to distant organs, but the lymph node burden is more substantial than at Stage II.

Stage IIIB

Stage IIIB is defined by tumor invasion into the chest wall or skin of the breast, which may appear as ulceration, peau d’orange (skin dimpling resembling orange peel), or satellite skin nodules. Inflammatory breast cancer (IBC) — an aggressive and rare subtype characterized by redness, swelling, and warmth of the breast caused by cancer cells blocking lymph vessels in the skin — is classified as Stage IIIB when there is no distant metastasis. IBC requires a different treatment approach than other breast cancers and is always treated with neoadjuvant (pre-surgery) chemotherapy first.

For more on breast cancer subtypes including inflammatory breast cancer, see breast cancer types.

Stage IIIC

Stage IIIC applies when cancer is found in:

  • 10 or more axillary lymph nodes, or

  • Infraclavicular lymph nodes (below the collarbone), or

  • Supraclavicular lymph nodes (above the collarbone), or

  • Internal mammary lymph nodes in combination with axillary lymph node involvement

The distinction between IIIB and IIIC is primarily anatomical. Stage IIIB involves chest wall or skin involvement, while IIIC is defined by more extensive lymph node spread.

Treatment for Stage III

Stage III breast cancer is typically approached with a multimodal strategy, often beginning with neoadjuvant chemotherapy to shrink the tumor before surgery. This sequence offers several advantages: it can make surgery more feasible, reduces the extent of surgery needed, and provides real-time information about how the tumor responds to treatment.

Key elements of Stage III treatment include:

  • Neoadjuvant chemotherapy — chemo given before surgery to reduce tumor size and assess treatment response

  • Surgery — often mastectomy, though lumpectomy may be possible after tumor shrinkage; evaluation of axillary lymph nodes

  • Radiation therapy — routinely recommended after surgery for Stage III to reduce local recurrence risk

  • Targeted therapy — for HER2-positive tumors, anti-HER2 agents (trastuzumab, pertuzumab) are integrated into the neoadjuvant and adjuvant treatment plan

  • Hormone therapy — for ER-positive tumors, typically for five to ten years after surgery; CDK4/6 inhibitors (abemaciclib, ribociclib) may be added for high-risk early-stage HR-positive disease

  • Immunotherapy (pembrolizumab) — for triple-negative breast cancer at Stage II/III, pembrolizumab combined with neoadjuvant chemotherapy followed by adjuvant (administered after surgery) pembrolizumab is now considered standard of care based on the KEYNOTE-522 trial. A 2024 overall survival analysis confirmed a 5% absolute survival advantage at five years (86.6% versus 81.7% for chemotherapy alone).

According to ACS and SEER data, 5-year survival rates range from approximately 57% to 86% across Stage III, with Stage IIIA carrying a better prognosis than Stage IIIC.

Stage IV: Metastatic Breast Cancer

What Stage IV Means

Stage IV breast cancer, also called metastatic or advanced breast cancer, means the cancer has spread from the breast to distant organs. The most common sites of metastasis are bone (the most frequent), liver, lung, and brain. Less commonly, cancer may spread to the skin, adrenal glands, or other sites.

It is important to know that some people are diagnosed with Stage IV breast cancer at their initial diagnosis (de novo metastatic breast cancer), while others develop metastatic disease after being treated for earlier-stage cancer. In either case, Stage IV breast cancer is generally considered incurable with current treatments, but it is increasingly manageable as a chronic condition. Many patients live for years, and some for a decade or more, with metastatic breast cancer, particularly with newer targeted therapies.

For a detailed look at breast cancer symptoms that can prompt diagnosis, or for information on the diagnostic process, see those dedicated guides.

Treatment for Stage IV

Treatment for Stage IV breast cancer is generally ongoing rather than time-limited. The primary goals shift from cure to disease control, symptom management, and maintaining quality of life for as long as possible. Treatment choices depend heavily on the tumor’s biological subtype:

Hormone receptor-positive (HR+), HER2-negative (the most common subtype, approximately 70% of metastatic breast cancer cases):

  • Hormone therapy remains the backbone — aromatase inhibitors, fulvestrant, or tamoxifen

  • CDK4/6 inhibitors (palbociclib/Ibrance, ribociclib/Kisqali, abemaciclib/Verzenio) combined with hormone therapy are standard of care in the first-line setting, extending progression-free survival by approximately two years compared to hormone therapy alone. Per NCCN guidelines, ribociclib plus an aromatase inhibitor is a Category 1 preferred first-line regimen.

  • PARP inhibitors (olaparib, talazoparib) for patients with BRCA1/2 mutations

  • Antibody-drug conjugates including T-DXd (trastuzumab deruxtecan/Enhertu) — approved in 2024 for HER2-low and HER2-ultralow HR-positive metastatic breast cancer that has progressed on one or more endocrine therapies

  • Chemotherapy when the cancer is no longer responding to hormone-based approaches

HER2-positive:

  • Anti-HER2 therapy is central: trastuzumab, pertuzumab, T-DM1 (ado-trastuzumab emtansine), T-DXd

  • In December 2025, the FDA approved T-DXd in combination with pertuzumab as a first-line treatment for HER2-positive metastatic breast cancer; this regimen demonstrated a median progression-free survival of 40.7 months compared to 26.9 months for the prior standard of care

  • Tucatinib (for patients with brain metastases), neratinib, and lapatinib provide additional options

Triple-negative breast cancer (TNBC):

  • Chemotherapy remains a cornerstone

  • Pembrolizumab (immunotherapy) for PD-L1-positive TNBC in the first-line metastatic setting

  • Sacituzumab govitecan (Trodelvy) — an antibody-drug conjugate approved for pretreated TNBC

  • PARP inhibitors for BRCA-mutated TNBC

  • T-DXd for TNBC with HER2 expression

Clinical trials are actively enrolling patients with metastatic breast cancer at all subtypes. Novel agents — including next-generation CDK inhibitors, PI3K pathway inhibitors, bispecific antibodies, and cellular therapies — are in development. Enrolling in a breast cancer clinical trial at Stage IV may offer access to treatments that have not yet reached standard practice.

5-Year Survival for Stage IV

According to ACS data based on SEER statistics (patients diagnosed 2014–2020), the 5-year relative survival rate for distant-stage (Stage IV) breast cancer is approximately 28–32% overall. However, this overall figure encompasses very different trajectories by subtype:

  • HR-positive, HER2-negative: Generally the longest survival, with some patients living five to ten or more years with modern treatments

  • HER2-positive: Survival has improved substantially with targeted therapies; HER2-positive patients have median overall survival approaching 42 months in some studies

  • Triple-negative: Historically shorter survival; immunotherapy is improving outcomes for PD-L1-positive TNBC

Importantly, survival statistics reflect patients diagnosed years ago and they do not capture the impact of newer drugs approved in 2023–2025. Many oncologists and researchers believe actual outcomes for patients diagnosed today are better than published survival statistics suggest.

For more detail on what these numbers mean for you individually, visit our guide on breast cancer survival rates.

How Biological Factors Modify Staging

Two tumors can look identical on an imaging scan — same size, same number of positive lymph nodes — and yet carry very different prognoses and require completely different treatment plans. The reason is biology.

ER and PR status (hormone receptor positive)

When breast cancer cells have receptors for estrogen (ER) and/or progesterone (PR), they are called hormone receptor-positive. This is the most common type of breast cancer. HR-positive tumors tend to grow more slowly, respond to hormone therapy, and carry a more favorable prognosis than HR-negative tumors of the same size and stage. However, HR-positive tumors can recur later, sometimes ten or fifteen years after initial treatment, which is why ongoing endocrine therapy for five to ten years is important.

HER2 status

HER2 (human epidermal growth factor receptor 2) is a protein that promotes cell growth. When a tumor overexpresses HER2 (HER2-positive), it tends to grow faster and behave more aggressively. The advent of anti-HER2 targeted therapies has transformed outcomes for HER2-positive breast cancer: what was once one of the hardest subtypes to treat is now among the most responsive to treatment.

Tumor grade

Grade reflects how different the cancer cells look from normal cells under a microscope. Grade 1 (low grade) cells look nearly normal and grow slowly. Grade 3 (high grade) cells look very abnormal and divide rapidly. Grade 2 is intermediate. Higher grade is associated with faster growth and greater risk of recurrence.

Ki-67

Ki-67 is a protein marker of cell proliferation — how quickly the cancer cells are dividing. A high Ki-67 index (generally above 20–30%) suggests a more aggressive tumor. It is commonly used alongside grade and receptor status to assess risk.

Genomic testing: Oncotype DX and beyond

For patients with early-stage, ER-positive, HER2-negative breast cancer — especially with node-negative or limited node-positive disease — genomic assays provide information that clinical staging cannot. The Oncotype DX Breast Recurrence Score assigns a number from 0 to 100: low scores indicate that chemotherapy is unlikely to add benefit beyond hormone therapy alone; high scores indicate that chemotherapy significantly reduces recurrence risk.

NCCN, ASCO, St. Gallen, and ESMO guidelines all incorporate Oncotype DX and similar tests into treatment decision-making. The test is also now embedded in the AJCC 8th edition staging tables: a patient with a low Oncotype DX score may be assigned to a lower prognostic stage than their TNM alone would indicate.

A Stage IIA HER2-positive tumor and a Stage IIA ER-positive, Grade 1 tumor may share an identical anatomic stage — but their treatment plans, prognoses, and follow-up protocols will differ substantially. This is why understanding your specific tumor biology, not just your stage number, is essential.

Recurrence: When Breast Cancer Returns

Successfully completing breast cancer treatment is a major milestone, but it is not the end of the story. Breast cancer can return after treatment. This is called recurrence.

Local or regional recurrence means the cancer comes back in the same breast, chest wall, or nearby lymph nodes. It is treated with surgery, radiation, and systemic therapies depending on the extent of the recurrence and the prior treatments used.

Distant recurrence means the cancer has spread to a distant organ. A distant recurrence, by definition, is reclassified as Stage IV metastatic breast cancer — even if the original diagnosis was Stage I or II.

The risk of recurrence is highest in the first five years after treatment, and monitoring during this period includes regular clinical exams and annual mammograms. However, ER-positive breast cancers carry a particular risk of late recurrence — cancer returning seven, ten, or even fifteen or more years after the original diagnosis. This is why oncologists often recommend extended adjuvant endocrine therapy (continuing hormone-blocking medication for up to ten years) for patients with higher-risk ER-positive disease.

Signs that may warrant evaluation include new bone pain, persistent cough, unexplained fatigue, changes in the treated breast or chest wall, or neurological symptoms. If you notice anything new or concerning, contact your medical team promptly. Early detection of recurrence allows for earlier intervention.

Frequently Asked Questions

What are the stages of breast cancer?

Breast cancer is classified into five stages: Stage 0 (DCIS — cancer cells confined to the milk ducts), Stage I (small tumor, no or minimal lymph node involvement), Stage II (larger tumor and/or limited lymph node spread), Stage III (locally advanced disease with significant lymph node involvement or skin/chest wall involvement), and Stage IV (cancer has spread to distant organs such as bone, lung, liver, or brain). Since 2018, staging also incorporates biological markers like ER, PR, and HER2 status, which can modify the stage designation up or down based on tumor biology.

What is the survival rate for each stage of breast cancer?

According to the American Cancer Society, using SEER data from patients diagnosed 2014–2020, the 5-year relative survival rates are approximately: Stage 0 (DCIS) — nearly 100%; Stage I — approximately 99%; Stage II/III (regional) — approximately 86%; Stage IV (distant) — approximately 28–32%. These numbers represent population averages and may not reflect your individual situation, which is shaped by tumor biology, overall health, age, and the specific treatments available today.

What does it mean when breast cancer spreads to lymph nodes?

When breast cancer cells travel to nearby lymph nodes — typically the axillary nodes under the arm — it indicates the cancer is beginning to move beyond the original tumor site. Lymph node involvement elevates the stage (from Stage I to Stage II or III, depending on the number of nodes involved) and generally signals the need for more systemic treatment, such as chemotherapy or extended hormone therapy. However, having cancer in a small number of lymph nodes does not mean the cancer has spread to distant organs, and many patients with lymph node-positive breast cancer achieve long-term remission.

Is stage 3 breast cancer curable?

Yes, Stage III breast cancer can be cured — many patients treated for Stage III breast cancer achieve long-term remission with no evidence of disease. The 5-year survival rate for Stage III ranges from approximately 57% to 86%, depending on whether it is IIIA, IIIB, or IIIC. Treatment is intensive, typically involving neoadjuvant chemotherapy, surgery, radiation, and targeted or hormone therapy depending on the tumor’s biology. For triple-negative Stage III breast cancer, adding pembrolizumab (immunotherapy) to chemotherapy has improved event-free survival rates, with approximately 84.5% of patients alive without disease recurrence at three years in the KEYNOTE-522 trial.

What is the difference between Stage IIIB and Stage IV breast cancer?

The critical distinction is whether the cancer has spread beyond the breast region. Stage IIIB means the tumor has grown into the chest wall or breast skin, or the patient has inflammatory breast cancer — but the cancer has not traveled to distant organs. Stage IV means the cancer has spread to distant organs such as bone, liver, lung, or brain. While Stage IIIB is locally advanced and requires aggressive treatment, it is still approached with curative intent. Stage IV treatment focuses on long-term disease control and quality of life rather than cure — though some patients achieve very long remissions, and survival times with metastatic breast cancer are improving.

Breast cancer clinical trials offer access to innovative treatments at every stage — from early-stage to metastatic disease. Ready to explore your options? Start your search with North’s trial finder.

References

  1. American Cancer Society. (2024). Survival Rates for Breast Cancer. https://www.cancer.org/cancer/types/breast-cancer/understanding-a-breast-cancer-diagnosis/breast-cancer-survival-rates.html

  2. American Cancer Society. (2024). Breast Cancer Facts & Figures 2024–2025. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/breast-cancer-facts-and-figures/2024/breast-cancer-facts-and-figures-2024.pdf

  3. Giuliano, A. E., Connolly, J. L., Edge, S. B., et al. (2017). Breast cancer — Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA: A Cancer Journal for Clinicians, 67(4), 290–303. https://acsjournals.onlinelibrary.wiley.com/doi/full/10.3322/caac.21393

  4. National Cancer Institute SEER Program. (2024). Cancer of the Breast (Female) — Cancer Stat Facts. https://seer.cancer.gov/statfacts/html/breast.html

  5. Schmid, P., Cortes, J., Pusztai, L., et al. (2020). Pembrolizumab for Early Triple-Negative Breast Cancer. New England Journal of Medicine, 382(9), 810–821. https://www.nejm.org/doi/full/10.1056/NEJMoa1910549

  6. ASCO Post. (2024). Overall Survival Analysis Confirms Pembrolizumab Regimen as Standard of Care for Triple-Negative Breast Cancer. https://ascopost.com/issues/october-25-2024/overall-survival-analysis-confirms-pembrolizumab-regimen-as-standard-of-care-for-triple-negative-breast-cancer/

  7. ASCO Post. (2025). T-DXd Approved by the FDA for Pretreated Patients With HER2-Low or -Ultralow Metastatic Breast Cancer. https://ascopost.com/issues/february-25-2025/t-dxd-approved-by-the-fda-for-pretreated-patients-with-her2-low-or-ultralow-metastatic-breast-cancer/

  8. Giaquinto, A. N., Sung, H., Miller, K. D., et al. (2024). Breast cancer statistics, 2024. CA: A Cancer Journal for Clinicians, 74(6), 477–495. https://acsjournals.onlinelibrary.wiley.com/doi/full/10.3322/caac.21863

  9. American Cancer Society. (2024). Treatment of Ductal Carcinoma in Situ (DCIS). https://www.cancer.org/cancer/types/breast-cancer/treatment/treatment-of-breast-cancer-by-stage/treatment-of-ductal-carcinoma-in-situ-dcis.html

  10. Exact Sciences. (2024). Oncotype DX Breast Recurrence Score Test. https://www.exactsciences.com/cancer-testing/oncotype-dx-breast-recurrence-score-providers

‹ Breast Cancer Symptoms: Early Signs, What to Watch For, and When to Act